Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Grade

About Tonix Pharmaceuticals Holding Corp.'s fundamentals

Tonix Pharmaceuticals is a small-cap biotechnology company with a market capitalization of $132.9 million that reported strong revenue growth of 29.9% year-over-year, indicating expanding commercial activity. However, the company operates at a significant loss, with a net margin of -946.2%, meaning it is spending substantially more than it generates in revenue. The company does not pay a dividend and reported a net loss in its latest annual statement, which is typical for early-stage biotechnology firms investing heavily in research and development and clinical trials.